Breath Therapeutics (Biotechnology, Health Care) — Funding, Investors & Signals 2026

Breath Therapeutics

Since 1906 our mission is innovating Cure & Care to make patients’ lives better.

Founded 2016 Italy

Italy 2468 employees Series A Total: $43.50M Biotechnology, Health Care +2

Breath Therapeutics was founded in 2016, with a mission to innovate Cure & Care for the betterment of patients' lives. As a subsidiary of Zambon SpA, the company is part of the Zambon group, a chemical-pharmaceutical company with a rich history and a commitment to improving patients' lives. With a presence in Europe, America, and Asia, the Zambon Group has over 2,900 employees and manufacturing units in Italy, Switzerland, France, China, and Brazil, with revenues amounting to 899 million euros in 2023. Zambon has expanded its focus beyond pain and respiratory and urological diseases to include treatments for serious conditions such as Parkinson’s Disease, Cystic Fibrosis, BOS, and NCFB. In recent years, the group established ZBiotech, a specialized biotech company aiming to develop a portfolio of patient-oriented drugs through scouting, acquisition, licensing, and development of new molecules. The company also manages the entire production chain through Zach-Zambon Chemicals, its partner for API, custom synthesis, and generic products. Through Zcube-Zambon Research Venture, the company actively supports the growth of innovative projects and startups, such as Careapt, founded in 2018, which develops integrated Hi-Tech/Hi-Touch solutions for chronic disease management. Additionally, Zambon also includes ItaliAssistenza, a Home Care Company that designs and delivers patient support programs and home care services. With its headquarters in Milan and a rich history dating back to 1906, Zambon is committed to transforming research into enterprise within the healthcare sector. The company's last investment was a €43.50M Series A investment on 08 March 2017, with key investors including Sofinnova Partners, Gilde Healthcare, and GIMV. In summary, Breath Therapeutics, as part of the Zambon group, presents a strong potential for innovative and patient-oriented solutions in the biotechnology and healthcare industries, with a solid financial backing from prominent investors.

Funding Stage	Amount	Investors	Lead Investors	Date
Series A	••••••	3		08 Mar 2017

Funding Stage

Amount

Investors

Lead Investors

Date

Series A

••••••

08 Mar 2017

FAQ About Breath Therapeutics

Since 1906 our mission is innovating Cure & Care to make patients’ lives better.

Breath Therapeutics was founded in 2016.

Breath Therapeutics is headquartered in Italy.

Breath Therapeutics operates in the following industries: Biotechnology, Health Care, Health and Wellness, Medical Devices.

Breath Therapeutics has approximately 2468 employees.

Breath Therapeutics has completed 1 funding round, raising a total of $43.50M. The latest funding stage is Series A.

Top alternatives and competitors to Breath Therapeutics include Zambon, Zambon España, Idoven, Kineta (Reverse Merger With Yumanity Therapeutics), AOP Health. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Breath Therapeutics and Zambon are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Breath Therapeutics

General Information

Track Breath Therapeutics

Discover More

About Breath Therapeutics

Funding Rounds & Investors (1)

Breath Therapeutics Alternatives & Competitors

FAQ About Breath Therapeutics

Don't just browse. Track.